QUIT net incomeQ3 2026-$12.11M
QUIT net income was -$12.11M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$14.44M a year earlier. For the full fiscal 2025 it was -$54.65M, compared with -$39.83M in fiscal 2024.
For the twelve months ended Sep 30, 2026, Achieve Life Sciences Inc. reported -$111.71M of net income.
QUIT net income was -$12.11M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$14.44M a year earlier. For the full fiscal 2025 it was -$54.65M, compared with -$39.83M in fiscal 2024.
QUIT diluted EPS was -$0.11 in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2025 it was -$1.25, compared with -$1.24 in fiscal 2024.
QUIT free cash flow was -$8.39M in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2025 it was -$49.47M.
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | $0 | $0 | - | - |
| Research and development | - | $22.82M | $15.81M | $30.08M | $23.97M | $6.88M | $9.67M | $5.87M | $3.10M | $286.0K |
| Selling, general and admin | - | $16.25M | $11.44M | $10.72M | $9.13M | $7.87M | $6.85M | $6.95M | $3.53M | $1.43M |
| Interest expense | $819.0K | $2.18M | $2.85M | $1.79M | - | - | - | - | - | - |
| Pre-tax income | -$54.65M | -$39.83M | -$29.82M | -$42.35M | -$33.15M | -$14.73M | -$16.39M | -$12.69M | -$13.63M | -$1.74M |
| Income tax | - | - | - | - | - | - | - | - | - | $0 |
| Net income | -$54.65M | -$39.83M | -$29.82M | -$42.35M | -$33.15M | -$14.73M | -$16.39M | -$12.69M | -$10.58M | -$1.23M |
| EPS, basic | -$1.25 | -$1.24 | -$1.50 | -$4.00 | -$4.08 | -$5.42 | -$39.76 | -$72.29 | -$441.40 | -$11625.00 |
| EPS, diluted | -$1.25 | -$1.24 | -$1.50 | -$4.00 | -$4.08 | -$5.42 | -$39.76 | -$72.29 | -$441.40 | -$11625.00 |
| Diluted shares | 43.6M | 32.1M | 19.8M | 10.6M | 8.1M | 2.7M | 412,320 | 175,511 | 23,972.1 | 106.15 |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $20.93M | $12.75M | $15.55M | $24.77M | $43.02M | $35.85M | $16.66M | $9.52M | $5.28M | $15.0K |
| Short-term investments | $15.47M | $21.61M | - | - | - | - | - | $5.09M | - | $10.23M |
| Receivables | - | - | - | - | - | - | $8.0K | $7.0K | $9.0K | $478.0K |
| Current assets | $39.89M | $36.47M | $16.98M | $27.33M | $44.59M | $36.98M | $17.33M | $15.54M | $5.91M | $18.0K |
| Goodwill | $1.03M | $1.03M | $1.03M | $1.03M | $1.03M | $1.03M | $1.03M | $1.03M | $1.03M | $1.03M |
| Total assets | $41.79M | $38.63M | $19.37M | $29.97M | $47.52M | $40.30M | $21.08M | $19.08M | $9.89M | $3.81M |
| Current liabilities | $9.08M | $6.68M | $20.81M | $21.60M | $4.55M | $2.94M | $2.87M | $3.27M | $2.01M | $3.07M |
| Total liabilities | $20.27M | $17.73M | $20.82M | $21.67M | $19.47M | $3.01M | $3.03M | $3.28M | $2.01M | $3.20M |
| Shareholders' equity | $21.52M | $20.90M | -$1.45M | $8.30M | $28.04M | $37.29M | $18.05M | $15.80M | $15.80M | $610.0K |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$49.47M | -$29.77M | -$24.48M | -$37.57M | -$29.44M | -$13.47M | -$15.22M | -$10.62M | -$9.11M | -$202.0K |
| Capital expenditures | $3.0K | - | $21.0K | - | - | $17.0K | $53.0K | $46.0K | - | $46.0K |
| Free cash flow | -$49.47M | - | -$24.50M | - | - | -$13.49M | -$15.27M | -$10.67M | - | -$248.0K |
| Investing cash flow | $6.11M | -$21.58M | -$21.0K | - | - | -$17.0K | $5.04M | -$5.13M | $12.65M | $10.61M |
| Financing cash flow | $51.53M | $48.53M | $15.28M | $19.32M | $36.61M | $32.68M | $17.32M | $19.76M | $2.00M | $150.0K |
| Stock-based compensation | $8.76M | $5.33M | $3.44M | $3.27M | $2.19M | $1.29M | $1.20M | $854.0K | $348.0K | $1.65M |
| Depreciation and amortization | $228.0K | $229.0K | $228.0K | $236.0K | $250.0K | $255.0K | - | - | - | - |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on equity | -254.0% | -190.6% | - | -510.1% | -118.2% | -39.5% | -90.8% | -80.3% | -67.0% | -202.3% |
| Return on assets | -130.8% | -103.1% | -153.9% | -141.3% | -69.8% | -36.6% | -77.8% | -66.5% | -107.0% | -32.4% |
| Current ratio | 4.39 | 5.46 | 0.82 | 1.27 | 9.80 | 12.60 | 6.04 | 4.75 | 2.93 | 0.01 |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | - | - | - | - | $5.32M | $6.71M | $7.10M | $7.30M | $7.61M | $5.11M | $2.80M | $2.11M |
| Selling, general and admin | - | - | - | - | $9.37M | $5.86M | $5.80M | $4.89M | $4.86M | $3.32M | $3.18M | $2.27M |
| Interest expense | $258.0K | $277.0K | $274.0K | $251.0K | $192.0K | $191.0K | $185.0K | $197.0K | $366.0K | $804.0K | $813.0K | $787.0K |
| Net income | -$12.11M | -$74.77M | -$10.17M | -$14.66M | -$14.44M | -$12.72M | -$12.83M | -$12.36M | -$12.51M | -$8.46M | -$6.49M | -$5.48M |
| EPS, basic | -$0.11 | -$0.80 | -$0.19 | - | -$0.28 | -$0.37 | -$0.37 | - | -$0.36 | -$0.25 | -$0.26 | -$0.23 |
| EPS, diluted | -$0.11 | -$0.80 | -$0.19 | - | -$0.28 | -$0.37 | -$0.37 | - | -$0.36 | -$0.25 | -$0.26 | -$0.23 |
| Diluted shares | 105.5M | 93.5M | 53.4M | - | 51.0M | 34.7M | 34.7M | - | 34.4M | 34.3M | 25.0M | - |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $59.74M | $47.96M | $28.08M | $20.93M | $31.93M | $51.87M | $13.02M | $12.75M | $9.54M | $14.76M | $66.40M | $15.55M |
| Short-term investments | $141.78M | $139.34M | $1.19M | $15.47M | $16.18M | $3.52M | $10.23M | $21.61M | $33.37M | $46.56M | - | - |
| Current assets | $203.41M | $188.29M | $31.06M | $39.89M | $50.05M | $56.90M | $25.00M | $36.47M | $45.53M | $62.52M | $67.71M | $16.98M |
| Goodwill | $1.03M | $1.03M | $1.03M | $1.03M | $1.03M | $1.03M | $1.03M | $1.03M | $1.03M | $1.03M | $1.03M | $1.03M |
| Total assets | $206.42M | $190.44M | $33.10M | $41.79M | $52.04M | $58.94M | $27.36M | $38.63M | $47.92M | $64.79M | $70.03M | $19.37M |
| Current liabilities | $19.39M | $197.66M | $11.83M | $9.08M | $9.73M | $8.57M | $7.13M | $6.68M | $6.72M | $13.70M | $20.57M | $20.81M |
| Total liabilities | $25.69M | $205.12M | $22.43M | $20.27M | $18.43M | $17.27M | $17.08M | $17.73M | $16.54M | $22.51M | $20.57M | $20.82M |
| Shareholders' equity | $180.73M | -$14.68M | $10.68M | $21.52M | $33.62M | $41.67M | $10.28M | $20.90M | $31.38M | $42.28M | $49.46M | -$1.45M |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.36M | -$10.78M | -$6.93M | -$17.98M | -$11.33M | -$9.07M | -$11.09M | -$9.19M | -$10.37M | -$4.92M | -$5.29M | -$4.36M |
| Capital expenditures | $33.0K | - | - | - | - | - | - | - | - | - | - | $6.0K |
| Free cash flow | -$8.39M | - | - | - | - | - | - | - | - | - | - | -$4.37M |
| Investing cash flow | -$1.66M | -$137.80M | $14.28M | $709.0K | -$12.65M | $6.70M | $11.35M | $11.72M | $13.27M | - | - | -$6.0K |
| Financing cash flow | $21.58M | $168.46M | $21.0K | $6.26M | $4.04M | - | - | $682.0K | -$8.11M | -$153.0K | $56.11M | $0 |
| Stock-based compensation | $7.70M | $6.96M | -$685.0K | $1.30M | $2.34M | $2.89M | $2.23M | $1.24M | $1.34M | $1.45M | $1.29M | -$10.0K |
| Depreciation and amortization | $63.0K | $58.0K | $57.0K | $57.0K | $54.0K | $55.0K | $62.0K | $58.0K | $57.0K | $57.0K | $57.0K | $57.0K |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 10.49 | 0.95 | 2.62 | 4.39 | 5.14 | 6.64 | 3.51 | 5.46 | 6.78 | 4.56 | 3.29 | 0.82 |
Source: XBRL data Achieve Life Sciences Inc. files with the SEC, latest filing dated Nov 10, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-10, first reported Nov 7, 2018; 1-for-20, first reported Aug 6, 2020.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| QUIT | - | - | -$111.71M | - | $697.7M |
| IDXX | $4.66B | +11.9% | $1.18B | 25.4% | $55.48B |
| ORKA | - | - | -$152.57M | - | $7.15B |
| LNTH | $1.56B | +2.4% | $269.90M | 17.3% | $6.64B |
| NEOG | $883.99M | -0.3% | -$56.10M | -6.3% | $2.45B |
| CLDX | $158.0K | -93.9% | -$309.06M | -195608.9% | $2.26B |
| NTLA | $52.89M | -8.1% | -$426.14M | -805.7% | $1.36B |
| QDEL | $2.59B | -4.5% | -$369.20M | -14.2% | $736.9M |
| ACHV | - | - | -$111.71M | - | $697.7M |